DeepMind spinout Isomorphic Labs partners with Eli Lilly and Novartis on AI-based drug discovery, for $82.5M paid upfront and $2.9B in performance incentives (Kyle Wiggers/TechCrunch)

DeepMind spinout Isomorphic Labs partners with Eli Lilly and Novartis on AI-based drug discovery, for $82.5M paid upfront and $2.9B in performance incentives (Kyle Wiggers/TechCrunch)

Kyle Wiggers / TechCrunch:
DeepMind spinout Isomorphic Labs partners with Eli Lilly and Novartis on AI-based drug discovery, for $82.5M paid upfront and $2.9B in performance incentives  —  Isomorphic Labs, the London-based, drug discovery-focused spin-out of Google AI R&D division DeepMind, today announced that it’s entered …